New hope for PAH patients: Extended-Release tacrolimus enters phase 3 trial
NCT ID NCT07612657
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 study tests VI-0106, an extended-release form of tacrolimus, in 300 people with pulmonary arterial hypertension (PAH) who still have trouble with daily activities despite taking standard PAH medications. Participants will receive either the drug or a placebo for 24 weeks to see if it improves their walking distance and delays disease worsening. The trial is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VI-0106 (extended-release tacrolimus)
- What this could lead to
- If successful, this could provide a new treatment option to improve exercise capacity and delay disease worsening for people with PAH who still have symptoms on current therapies.
- What could go wrong
- This is a Phase 3 trial, but PAH is a complex disease and previous tacrolimus studies have shown mixed results. The drug may cause side effects like kidney problems or infections, and it requires lifelong use alongside other PAH medications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an inhaled therapy replace a daily pill for PAH?
- Can a new pill ease the strain of pulmonary arterial hypertension?
- Could a gut bacteria transplant ease a rare lung disease?
- Can a diabetes drug help the heart burn fuel better in pulmonary hypertension?
- Can a Real-World registry improve how treprostinil is used for PAH?
- Can a smartwatch replace the clinic walk test for lung disease patients?